MAM
AVEO

Meeder Asset Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Meeder Asset Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-247
Closed -$4K – 1954
2018
Q4 		$4K Sell
247
-1,074
-81% -$23.6K ﹤0.01% 1493
2018
Q3 		$44K Buy
1,321
+882
+201% +$22.7K ﹤0.01% 824
2018
Q2 		$9.91K Buy
+439
New +$10.4K ﹤0.01% 1130

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Meeder Asset Management's AVEO Position: Q1 2019 in Review

Meeder Asset Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2019, closing a stake of 247 shares — an estimated $4K sold.

Meeder Asset Management first reported a position in AVEO in Q2 2018 and held it in 3 quarters. The position peaked at $44K in Q3 2018. 83 funds tracked by Wall St. Rank hold AVEO as of Q1 2019.

  • Meeder Asset Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Meeder Asset Management sold 247 AVEO Pharmaceuticals, Inc. shares in Q1 2019, an estimated $4K.
  • Meeder Asset Management first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2018 and held it in 3 quarters.
  • Meeder Asset Management's AVEO Pharmaceuticals, Inc. position peaked at $44K in Q3 2018.
  • 83 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2019.

Based on Meeder Asset Management's 13F filing for Q1 2019, filed 16 Apr 2019.